Myokardia Inc.

Plus: Jazz acquires Chimerix for 72% premium, and J&J does not exercise HexaBody Genmab option, Myokardia ends partnership with Fulcrum

Aficamten appears to have slight edge over Camzyos in increasing peak oxygen uptake

Plus: CCO Olinger leaving Amylyx and updates from Coherus, Compass and NanoMosaic

Plus: Rampart raises $85M series A for DNA-based therapies and updates from Servier, Novartis, Cargo and more

BioCentury’s roundup of translational news

As blockbusters lose patent exclusivity, pharma believes nine-product portfolio has $25B long-term potential

Plus: Mestag names Logtenberg as chair and updates from Edgewise, Myriad and Venatorx

Plus 5AM adds Arthur Tzianabos, June Lee as venture partners, and updates from Woebot, Flagship Biosciences and Radionetics

Plus Integra’s Caruso passes away and updates from Ambrx, Cullinan, Zephyr, South Rampart and more

Plus Generate hires Goldman Sachs veteran Jason Silvers as CFO, and updates from HotSpot, Berkeley Lights and more